|
業務類別
|
Medical Instruments & Supplies |
|
業務概覽
|
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively. |
| 公司地址
| 41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453 |
| 電話號碼
| +1 781 250-0111 |
| 傳真號碼
| +1 781 250-0115 |
| 公司網頁
| https://www.repligen.com |
| 員工數量
| 2000 |
| Ms. Violetta A. Hughes |
Chief Accounting Officer |
-- |
26/02/2026 |
| Mr. Olivier Loeillot |
Director, President and Chief Executive Officer |
美元 650.00K |
26/02/2026 |
| Mr. Ralf Kuriyel, PhD |
Senior Vice President, Research and Development |
美元 396.74K |
04/04/2025 |
| Mr. James R. Bylund |
Chief Operating Officer |
美元 467.18K |
04/04/2025 |
| Mr. Jason K. Garland |
Chief Financial Officer |
美元 550.00K |
26/02/2026 |
|
|
| Mr. Olivier Loeillot |
Director, President and Chief Executive Officer |
26/02/2026 |
| Ms. Margaret A. Pax |
Independent Director |
26/02/2026 |
| Dr. Konstantin Konstantinov, PhD |
Independent Director |
26/02/2026 |
| Dr. Rohin Mhatre, PhD |
Independent Director |
26/02/2026 |
| Mr. Tony J. Hunt |
Executive Chairman of the Board |
06/01/2026 |
| Ms. Carrie Eglinton Manner |
Independent Director |
26/02/2026 |
| Dr. Martin D. Madaus,PhD |
Independent Director |
06/01/2026 |
| Mr. Nicolas M. Barthelemy |
Independent Director |
26/02/2026 |
| Ms. Karen A. Dawes, M.A. |
Lead Independent Director |
26/02/2026 |
| Mr. Glenn P. Muir |
Independent Director |
26/02/2026 |
|
|
|
|
